Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Corbus Pharmaceuticals ( (CRBP) ) has shared an update.
Corbus Pharmaceuticals has secured FDA Fast Track designation for its innovative drug CRB-701, aimed at treating relapsed or refractory metastatic cervical cancer. This promising next-generation antibody drug conjugate specifically targets Nectin-4 and is currently undergoing a Phase 1 clinical trial to assess its safety and efficacy. Investors eagerly anticipate initial results from the study in early 2025, highlighting a potential breakthrough in oncology treatment.
Learn more about CRBP stock on TipRanks’ Stock Analysis page.
